OBJECTIVE: The objective was to evaluate the diagnostic performance of FS for sentinel lymph node biopsy.
METHODS: Eligibility criteria: Studies where SLNB was performed using FS.
METHODS: PubMed, EMBASE, Cochrane library and online clinical trial registers. Risk of bias: Articles were assessed for risk of bias using the QUADAS-2 tool.
RESULTS: The main summary measures were pooled Sentinel Lymph Node Identification Rate (SLN-IR) and pooled False Negative Rate (FNR) using random-effects model.
RESULTS: A total of 45 articles were retrieved by the initial systematic search. 7 out of the 45 studies comprising a total of 332 patients were included in the meta-analysis. The pooled SLN-IR was 93.2% (95% confidence interval [CI], 0.87-0.97; 87% to 97%). Five validation studies were included for pooling the false negative rate and included a total of 211 patients. The pooled FNR was 5.6% (95% confidence interval [CI], 2.9-9.07).
CONCLUSIONS: Fluorescein-guided SLNB is a viable option for detection of lymph node metastases in clinically node negative patients with early breast cancer. It achieves a high pooled Sentinel Lymph Node Identification Rate (SLN-IR) of 93% with a false negative rate of 5.6% for the detection of axillary lymph node metastasis.
目的:目的是评估FS对前哨淋巴结活检的诊断性能。
方法:合格标准:使用FS进行SLNB的研究。
方法:PubMed,EMBASE,Cochrane图书馆和在线临床试验登记册。偏倚风险:使用QUADAS-2工具评估文章的偏倚风险。
结果:主要的总结措施是使用随机效应模型的合并前哨淋巴结识别率(SLN-IR)和合并假阴性率(FNR)。
结果:初步系统检索共检索到45篇。45项研究中有7项包括总共332名患者,纳入了荟萃分析。合并的SLN-IR为93.2%(95%置信区间[CI],0.87-0.97;87%至97%)。包括五项验证研究以汇集假阴性率,总共包括211名患者。合并的FNR为5.6%(95%置信区间[CI],2.9-9.07)。
结论:荧光素引导的SLNB是检测临床淋巴结阴性早期乳腺癌患者淋巴结转移的可行选择。它实现了93%的高合并前哨淋巴结识别率(SLN-IR),用于检测腋窝淋巴结转移的假阴性率为5.6%。